target directory

glp 1 receptor clinical trial intelligence

Trials are included when the normalized target field matches this target directory. Full protocol, result, eligibility and IP analysis is available inside the premium workspace.

Validated reports

Directory type

target

Association rule

normalized field

NCT06621017

Source recordAI-normalized

A Randomized, Placebo-Controlled, Double-Blind, Parallel-Group Study Evaluating the Efficacy, Safety, and Pharmacokinetics of Daily Administrations of the GLP-1 Analogue ROSE-010 on Appetite and Food Intake in Overweight and Obese Subjects

ROSE-010, a GLP-1 analogue, targets appetite regulation in overweight and obese female subjects. The obesity treatment market is expanding, driven by increasing prevalence and demand for effective weight management solutions. Competitive landscape includes established GLP-1 receptor agonists like liraglutide and semaglutide, as well as emerging therapies. Successful trial outcomes could position Rose Pharma Inc favorably within this lucrative market, but potential regulatory hurdles and market access strategies will require careful consideration.

AI analysis

Indication: Obesity; Overweight

Modality: small molecule

Target: GLP-1 receptor

Sponsor: Rose Pharma Inc

Source URL: ClinicalTrials.gov

Source updated: Detailed source ingestion pending

Ingested: Jul 31, 2026

Model: trialsignal-ai-v1

Validation: validated

Matched by target_normalized: GLP-1 receptor

View original source fields

Condition raw: Obesity; Overweight

Condition normalized: Obesity; Overweight

Modality raw: small molecule

Modality normalized: small molecule

Target raw: GLP-1 receptor

Target normalized: GLP-1 receptor

Open report

NCT01917656

Source recordAI-normalized

Efficacy and Safety of Liraglutide Versus Sulphonylurea Both in Combination With Metformin During Ramadan in Subjects With Type 2 Diabetes

The trial evaluates liraglutide, a GLP-1 receptor agonist, against sulphonylurea in combination with metformin for managing Type 2 Diabetes Mellitus (T2DM) during Ramadan fasting. Given the increasing prevalence of diabetes in Muslim populations, particularly in Africa and Asia, successful outcomes could enhance liraglutide's market position against established therapies like sulphonylureas. The results may support expanded indications for liraglutide, potentially increasing its market share in diabetes management. Competitive implications include the need for Novo Nordisk to monitor responses from other diabetes therapies, particularly those targeting fasting-related glycemic control. Diligence should focus on the safety profile and patient adherence during fasting periods, which could influence prescribing patterns.

AI analysis

Indication: Diabetes

Modality: small molecule

Target: GLP-1 receptor

Sponsor: Novo Nordisk A/S

Source URL: ClinicalTrials.gov

Source updated: Detailed source ingestion pending

Ingested: Jul 21, 2026

Model: trialsignal-ai-v1

Validation: validated

Matched by target_normalized: GLP-1 receptor

NCT04885634

Source recordAI-normalized

Semaglutide for the Reduction of Arrhythmia Burden in Overweight and Obese Patients With Atrial Fibrillation (Pilot Study)

The pilot study of semaglutide for reducing arrhythmia burden in overweight and obese patients with atrial fibrillation (AF) aims to explore a novel application of an established GLP-1 receptor agonist. Given the increasing prevalence of obesity and AF, successful outcomes could position semaglutide as a dual therapeutic option, enhancing its market potential beyond diabetes and weight management. However, the study has been withdrawn due to lack of funding, which raises concerns about the feasibility of advancing this indication without significant investment. Competitive analysis indicates that while semaglutide is well-positioned in the obesity and diabetes markets, the AF indication may face challenges from existing antiarrhythmic therapies and emerging treatments targeting similar patient populations.

AI analysis

Indication: Atrial Fibrillation

Modality: small molecule

Target: GLP-1 receptor

Sponsor: Axel Brandes

Source URL: ClinicalTrials.gov

Source updated: Detailed source ingestion pending

Ingested: Jul 17, 2026

Model: trialsignal-ai-v1

Validation: validated

Matched by target_normalized: GLP-1 receptor

NCT03371862

Source recordAI-normalized

Pilot Study of the GLP-1 Agonist, Liraglutide, on Decreasing Parenteral Support Requirements in Short Bowel Patients.

The pilot study of Liraglutide (Victoza), a GLP-1 agonist, aims to assess its efficacy in reducing parenteral support requirements in patients with short bowel syndrome. This indication represents a niche but potentially lucrative market, given the limited treatment options for short bowel syndrome. The failure to recruit participants due to COVID-19 highlights the challenges in conducting clinical trials during global health crises, which may impact timelines and investor confidence. The competitive landscape includes other GLP-1 agonists and novel therapies targeting gastrointestinal disorders, necessitating a thorough diligence process to evaluate market positioning and potential partnerships.

AI analysis

Indication: Short Bowel Syndrome

Modality: small molecule

Target: GLP-1 receptor

Sponsor: Imperial College London

Source URL: ClinicalTrials.gov

Source updated: Detailed source ingestion pending

Ingested: Jul 15, 2026

Model: trialsignal-ai-v1

Validation: validated

Matched by target_normalized: GLP-1 receptor

View original source fields

NCT00423501

Source recordAI-normalized

A Double Blind, Placebo-controlled, Dose-ranging Study to Investigate the Effect on Glycemic Control, Safety, Pharmacokinetics and Pharmacodynamics of GLP-1 in Patients With Type 2 Diabetes Mellitus Treated With a Stable Dose of Metformin.

The clinical trial conducted by Hoffmann-La Roche evaluates a GLP-1 analogue, taspoglutide, in patients with Type 2 Diabetes Mellitus who are on stable metformin therapy. Given the increasing prevalence of diabetes and the growing market for GLP-1 receptor agonists, successful outcomes could position taspoglutide favorably against established competitors such as liraglutide and semaglutide. The trial's completion and the anticipated efficacy and safety data will be critical for strategic positioning in a competitive landscape that includes both established and emerging therapies. The target population of 100-500 individuals indicates a robust dataset that could support regulatory filings and market entry strategies.

AI analysis

Indication: Diabetes Mellitus Type 2

Modality: small molecule

Target: GLP-1 receptor

Sponsor: Hoffmann-La Roche

Source URL: ClinicalTrials.gov

Source updated: Detailed source ingestion pending

Ingested: Jul 10, 2026

Model: trialsignal-ai-v1

Validation: validated

Matched by target_normalized: GLP-1 receptor